Literature DB >> 18394447

Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital.

Nancy M Allen Lapointe1, Jie-Lena Sun, Sigal Kaplan, Phil d'Almada, Sana M Al-Khatib.   

Abstract

Little is presently known regarding whether a rhythm-control or a rate-control strategy is more frequently used in patients hospitalized for atrial fibrillation (AF). This study was conducted to assess patient and physician characteristics associated with each treatment strategy and with the use of anticoagulants. Hospitalizations for primary diagnoses of AF were examined using hospital claims from January 2000 to December 2004. Patients who received antiarrhythmic drugs, ablation, or cardioversion for AF were categorized as receiving rhythm control. Patients managed only with beta blockers, calcium channel blockers, or digoxin were categorized as receiving rate control. Characteristics associated with rhythm compared with rate control and anticoagulant use with CHADS(2) score were determined. The study cohort included 155,731 hospitalizations from 464 hospitals. Of these, 75,397 (48%) were categorized as involving rhythm control and 80,334 (52%) as involving rate control. Care by a noncardiologist (adjusted odds ratio [OR] 0.33, 95% confidence interval [CI] 0.31 to 0.36) and increasing age >65 years (adjusted OR 0.87, 95% CI 0.86 to 0.88) were associated with lower odds of rhythm versus rate control; hypertrophic cardiomyopathy was associated with greater odds (adjusted OR 2.3, 95% CI 1.81 to 2.84) of rhythm control. Warfarin use was greater in the rhythm-control group compared with the rate-control group (adjusted OR 1.56, 95% CI 1.52 to 1.60), and warfarin use was greater with a CHADS(2) score > or =2 (unadjusted OR 1.21, 95% CI 1.19 to 1.24). In conclusion, rhythm- and rate-control strategies were used equally in patients hospitalized for AF. Some observations, such as greater use of the rate-control strategy with increasing age, were consistent with recommendations, but others, such as lower use of warfarin in the rate-control group, were not.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394447     DOI: 10.1016/j.amjcard.2007.11.067

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation.

Authors:  Nancy M Allen LaPointe; Yuliya Lokhnygina; Gillian D Sanders; Eric D Peterson; Sana M Al-Khatib
Journal:  Am Heart J       Date:  2013-09-24       Impact factor: 4.749

2.  Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice.

Authors:  Annabelle Cumyn; Nadine Sauvé; Évelyne Rey
Journal:  Obstet Med       Date:  2017-01-29

3.  Center variation in hospital costs for patients undergoing congenital heart surgery.

Authors:  Sara K Pasquali; Jie-Lena Sun; Phil d'Almada; Robert D B Jaquiss; Andrew J Lodge; Neal Miller; Alex R Kemper; Carole M Lannon; Jennifer S Li
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.